Adage Capital Partners
CMPX icon

Adage Capital Partners’s Compass Therapeutics CMPX Stock Holding History

Adage Capital Partners’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.6M Sell
1,186,500
-7,300,000
-86% -$21.6M ﹤0.01% 856
2026
Q1 		$44.9M Buy
8,486,500
+4,050,000
+91% +$23.4M 0.07% 273
2025
Q4 		$23.8M Sell
4,436,500
-750,000
-14% -$3.46M 0.04% 429
2025
Q3 		$18.2M Buy
5,186,500
+761,632
+17% +$2.41M 0.03% 496
2025
Q2 		$11.5M Buy
4,424,868
+449,868
+11% +$928K 0.02% 587
2025
Q1 		$7.55M Sell
3,975,000
-2,019,810
-34% -$5.37M 0.01% 638
2024
Q4 		$8.69M Sell
5,994,810
-5,135,190
-46% -$8.53M 0.02% 638
2024
Q3 		$20.5M Hold
11,130,000
– – 0.04% 442
2024
Q2 		$11.1M Hold
11,130,000
– – 0.02% 577
2024
Q1 		$22M Buy
11,130,000
+1,250,000
+13% +$2.16M 0.04% 423
2023
Q4 		$15.4M Buy
9,880,000
+3,500,000
+55% +$6.06M 0.03% 500
2023
Q3 		$12.6M Buy
6,380,000
+130,000
+2% +$321K 0.03% 523
2023
Q2 		$19.9M Hold
6,250,000
– – 0.04% 406
2023
Q1 		$20.4M Buy
6,250,000
+475,200
+8% +$1.87M 0.05% 408
2022
Q4 		$29M Buy
5,774,800
+1,168,200
+25% +$4.66M 0.07% 325
2022
Q3 		$10.5M Buy
4,606,600
+200,000
+5% +$554K 0.03% 624
2022
Q2 		$11.7M Buy
4,406,600
+2,129,600
+94% +$4.62M 0.03% 633
2022
Q1 		$3.12M Buy
2,277,000
+877,000
+63% +$1.81M 0.01% 873
2021
Q4 		$4.44M Buy
+1,400,000
New +$4.64M 0.01% 826

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Adage Capital Partners's CMPX Position: Q2 2026 in Review

Adage Capital Partners reduced its Compass Therapeutics (CMPX) stake by 86% in Q2 2026, selling an estimated $21.6M and leaving 1,186,500 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #856.

Adage Capital Partners first reported a position in CMPX in Q4 2021 and has held it in 19 quarters since. The position peaked at $44.9M in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Adage Capital Partners held 1,186,500 shares of Compass Therapeutics worth $2.6M as of Q2 2026.
  • Adage Capital Partners sold 7,300,000 Compass Therapeutics shares in Q2 2026, an estimated $21.6M.
  • Compass Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q2 2026, its #856 holding.
  • Adage Capital Partners first reported a position in Compass Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Adage Capital Partners's Compass Therapeutics position peaked at $44.9M in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.